+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07562178

Pemafibrate Treatment to Prevent Worsening of Symptomatic Intracranial Artery Stenosis and Reduce Vascular Risk A Randomized Open-Label Study

Led by Tokyo Women's Medical University · Updated on 2026-11-03

270

Participants Needed

42

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether pemafibrate can help prevent worsening of intracranial arterial stenosis ICAS in people who have symptomatic ICAS and high triglyceride levels after an ischemic stroke or transient ischemic attack TIA. This open-label, randomized, parallel-group trial compares a group receiving pemafibrate with a group not receiving it, while all participants continue standard stroke care including antithrombotic therapy and management of vascular risk factors. The study is sponsored by Tokyo Womens Medical University. Participants assigned to the pemafibrate group will take the drug for 12 months, with possible dose adjustments based on triglyceride levels and kidney function. Both groups will receive standard medical therapy. Brain CT angiography CTA will be performed at the start and after 12 months. Additional assessments include brain MRIMRA and vascular tests such as ankle brachial index, cardio ankle vascular index, and pulse wave velocity, conducted according to the study schedule. During the study, participants will have blood tests and clinical assessments at baseline and follow-up visits. Researchers will monitor vascular events, functional outcomes, and adverse events over 12 months. The main outcome measured is progression of intracranial arterial stenosis on CTA at 12 months. Secondary outcomes include changes in stenosis severity, cardiovascular events, mortality, daily living activities, brain imaging markers, vascular indices, blood biomarkers, and safety measures throughout the treatment period.

CONDITIONS

Brief Title

Pemafibrate for Symptomatic ICAS RCT

Research Team

K

Kenichi Todo, MD, PhD

T

Takao Hoshino, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here